APG-2575 + lenalidomide + dexamethasone

APG-2575 + lenalidomide + dexamethasone is a combination therapy under clinical investigation for the treatment of relapsed or refractory multiple myeloma. - **APG-2575 (lisaftoclax)** is an oral, small molecule inhibitor targeting BCL-2, a protein that prevents apoptosis in cancer cells, thus promoting programmed cell death in BCL-2 dependent hematologic malignancies. - **Lenalidomide** is an oral immunomodulatory drug (IMiD) that inhibits proliferation of myeloma cells, supports immune surveillance by stimulating T and NK cells, and impedes blood vessel formation that supplies the myeloma. - **Dexamethasone** is a synthetic corticosteroid used to reduce inflammation and suppress immune responses in the treatment of hematologic malignancies[1][3][5]. The combination exploits the complementary mechanisms of BCL-2 inhibition, immune modulation, and anti-inflammatory activity to overcome resistance to standard therapies in relapsed/refractory multiple myeloma[1][3][5].